Showcases Stock ranks Forex

Clarus Therapeutics Hldgs Inc (CRXT)
0.308  0.005 (1.55%) 08-08 16:00
Open: 0.2991 Pre. Close: 0.3033
High: 0.308 Low: 0.295
Volume: 918,092 Market Cap: 16M
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.31 - 0.312 0.312 - 0.313
Low: 0.287 - 0.288 0.288 - 0.29
Close: 0.308 - 0.31 0.31 - 0.312
Stock Technical Analysis
Target: Six months: 0.43
One year: 0.51
Support: Support1: 0.26
Support2: 0.22
Resistance: Resistance1: 0.37
Resistance2: 0.44
Pivot: 0.31
Moving Averages: MA(5): 0.30
MA(20): 0.33
MA(100): 0.67
MA(250): 2.71
MACD: MACD(12,26): -0.03
Signal(12,26,9): -0.03
%K %D: %K(14,3): 32.44
%D(3): 26.61
RSI: RSI(14): 41.02
52-Week: High: 31.24
Low: 0.261
Change(%): -97.0
Average Vol(K): 3-Month: 3441
10-Days: 1081
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

[ CRXT ] has closed above bottom band by 49.9%. Bollinger Bands are 82.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 61 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Thu, 28 Jul 2022
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate) - Yahoo Finance

Wed, 25 May 2022
Is Clarus Therapeutics Holdings Inc (CRXT) a Good Choice in Drug Manufacturers - General Wednesday? - InvestorsObserver

Mon, 16 May 2022
Clarus Therapeutics Holdings, Inc. (CRXT) CEO Bob Dudley on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha

Thu, 12 May 2022
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results - GlobeNewswire

Mon, 25 Apr 2022
Clarus Therapeutics Holdings Inc (CRXT) is down 25.00% Monday In Premarket Trading - InvestorsObserver

Mon, 25 Apr 2022
Clarus Therapeutics plunges 22% on equity offering (NASDAQ:CRXT) - Seeking Alpha

Financial Analysis
Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. (M) 52.02
Shares Float (M) 32.02
% Held by Insiders 2.59
% Held by Institutions 23.39
Shares Short (K) 2000
Shares Short Prior Month (K) 3310
Stock Financials
EPS -2.800
Book Value (p.s.) -1.230
Profit Margin -256.16
Operating Margin -271.72
Return on Assets (ttm) -89.5
Return on Equity (ttm)
Qtrly Rev. Growth 72.1
Gross Profit (p.s.) 0.216
Sales Per Share 0.301
EBITDA (p.s.) -0.816
Qtrly Earnings Growth
Operating Cash Flow (M) -54.01
Levered Free Cash Flow (M) -43.12
Stock Valuation
PE Ratio -0.11
PEG Ratio
Price to Book value -0.25
Price to Sales 1.02
Price to Cash Flow -0.30
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android